Sandostatin — CareFirst (Caremark)
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Reauthorization criteria
- Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy
Approval duration
12 months